Igor Lifirenko

6.0k total citations
4 papers, 182 citations indexed

About

Igor Lifirenko is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Infectious Diseases. According to data from OpenAlex, Igor Lifirenko has authored 4 papers receiving a total of 182 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 2 papers in Radiology, Nuclear Medicine and Imaging and 1 paper in Infectious Diseases. Recurrent topics in Igor Lifirenko's work include HER2/EGFR in Cancer Research (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Fungal Infections and Studies (1 paper). Igor Lifirenko is often cited by papers focused on HER2/EGFR in Cancer Research (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Fungal Infections and Studies (1 paper). Igor Lifirenko collaborates with scholars based in Russia, Poland and Belarus. Igor Lifirenko's co-authors include Per Soelberg Sørensen, Ágnes Ruzsa, Paul M. Clément, Gábor Répássy, Jean-Pascal Machiels, Tina Nielsen, Steen Lisby, Vladimir Moiseyenko, Justin Stebbing and Joanna Pikiel and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Igor Lifirenko

4 papers receiving 177 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Igor Lifirenko Russia 4 118 96 83 40 34 4 182
Eve‐Marie Neidhardt France 9 104 0.9× 100 1.0× 71 0.9× 83 2.1× 55 1.6× 28 249
J. Miroir France 8 143 1.2× 153 1.6× 66 0.8× 30 0.8× 85 2.5× 26 237
Franck Drouet France 7 103 0.9× 52 0.5× 70 0.8× 35 0.9× 41 1.2× 10 167
Yan-Fang Ye China 7 76 0.6× 101 1.1× 44 0.5× 21 0.5× 47 1.4× 7 167
Dtt Chua China 7 151 1.3× 229 2.4× 88 1.1× 76 1.9× 181 5.3× 10 352
Cédrik Lafond France 8 181 1.5× 172 1.8× 109 1.3× 22 0.6× 78 2.3× 12 260
Umair Mahmood United States 7 49 0.4× 89 0.9× 72 0.9× 44 1.1× 52 1.5× 16 200
Olivier Ballivy Canada 8 67 0.6× 74 0.8× 92 1.1× 32 0.8× 36 1.1× 14 194
Neus Basté Spain 10 213 1.8× 142 1.5× 114 1.4× 56 1.4× 81 2.4× 32 335
María José Echarri Spain 5 101 0.9× 19 0.2× 71 0.9× 42 1.1× 15 0.4× 7 146

Countries citing papers authored by Igor Lifirenko

Since Specialization
Citations

This map shows the geographic impact of Igor Lifirenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor Lifirenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor Lifirenko more than expected).

Fields of papers citing papers by Igor Lifirenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor Lifirenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor Lifirenko. The network helps show where Igor Lifirenko may publish in the future.

Co-authorship network of co-authors of Igor Lifirenko

This figure shows the co-authorship network connecting the top 25 collaborators of Igor Lifirenko. A scholar is included among the top collaborators of Igor Lifirenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Igor Lifirenko. Igor Lifirenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

4 of 4 papers shown
1.
Esteva, Francisco J., Alexey Manikhas, Vladimir Moiseyenko, et al.. (2017). Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC). Annals of Oncology. 28. v44–v45. 5 indexed citations
2.
Stebbing, Justin, Alexey Manikhas, Vladimir Moiseyenko, et al.. (2017). Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).. Journal of Clinical Oncology. 35(15_suppl). 510–510. 9 indexed citations
3.
Nechaeva, Marina, Olga Burdaeva, Vladimir Vladimirov, et al.. (2015). Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study.. Journal of Clinical Oncology. 33(15_suppl). e20735–e20735. 5 indexed citations
4.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eve‐Marie Neidhardt Breakdown of academic impact, for papers by J. Miroir Breakdown of academic impact, for papers by Franck Drouet Breakdown of academic impact, for papers by Yan-Fang Ye Breakdown of academic impact, for papers by Dtt Chua Breakdown of academic impact, for papers by Cédrik Lafond Breakdown of academic impact, for papers by Umair Mahmood Breakdown of academic impact, for papers by Olivier Ballivy Breakdown of academic impact, for papers by Neus Basté Breakdown of academic impact, for papers by María José Echarri
Rankless by CCL
2026